Additional studies showed that treatment with γ-tocotrienol, rosiglitazone, or GW9662 alone or in combination had no effect of PPARγ expression in +SA mouse mammary tumor cells as compared to the vehicle-treated control group (Figure 4(b)). Here, PPARG is linked to breast cancer.